Phase 2 N=161 Tau Screening Study in Subjects With Early Symptomatic AD
Alzheimer Disease
Primary: Flortaucipir Qualitative Results (Visual Reads) — 51; 13; 1; 65 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=140 Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)
Hemorrhage, Surgical · Blood Loss, Surgical · Blood Loss, Postoperative
Primary: Incidence of Perioperative (Periop) Bleeding, Primary Effectiveness Composite Endpoint, Modified Intent to Treat (mITT) Population — 2103; 2244 number of wins — p=0.748
Phase 2 N=155 Tau Screening Study in Patients With Early Symptomatic AD
Alzheimer Disease
Primary: Flortaucipir Qualitative Results (Visual Reads) — 56; 22; 78; 2 Participants
N/A N=121 Trauma Survivors Outcomes and Support Study IV
Posttraumatic Stress Disorder · Depression · Suicide
Primary: Change in Post Traumatic Stress Disorder (PTSD) Symptoms Over the Course of the Six Months After Injury — 47.0; 47.0; 43.9; 43.6 units on a scale — p=0.05
N/A N=150 TeamTRACS Pilot (CTSI)
Teamwork · Implementation
Primary: Change in Teamwork Knowledge From Baseline to 3-month Follow-up — 75.60; 74.72; 80.00; 75.00 percentage correct answers — p=.03
N/A N=2,057 The Tobacco, Alcohol, Prescription Medication and Other Substances Tool
Substance Use Disorder
Primary: Diagnostic and Statistical Manual-5 (DSM-5) Alcohol Use Disorder Diagnosis Measured by the Modified World Mental Health Composite International Diagnostic Interview…
N/A N=184 Comparing TR Band to Statseal in Conjunction With TR Band
Arterial Occlusion · Angina Pectoris · Cardiovascular Diseases
Primary: Time to Hemostasis Using the Hemostasis Management System (HMS) — 160; 42.95 minutes
Phase 3 N=726 TASALL - TachoSil® Against Liquor Leak
Cerebrospinal Fluid Leaks
Primary: Percentage of Participants With Clinically Evident Verified Post-Operative Cerebrospinal Fluid Leak or Clinically Evident Pseudomeningocele or Treatment Failure — 6.9…
N/A N=302 ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss
Obesity
Primary: Mean Percent Total Body Weight Loss (% TBL) Between the TPS and the Control Group — 9.5; 2.8 % Total Body Weight Loss — p=<0.0001
Phase 3 N=903 Study of Tranexamic Acid During Air and Ground Medical Prehospital Transport Trial (STAAMP Trial)
Traumatic Hemorrhage
Primary: 30 Day Mortality — 36; 45 Participants
N/A N=194 Threshold Suspend in Pediatrics at Home
Type 1 Diabetes
Primary: Overall Mean Change in A1C — 0.26 percentage
N/A N=213 Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries
Peripheral Artery Disease
Primary: Efficacy - Number of Subjects That Met Primary Patency Criteria at 12 Months — 120 Participants
N/A N=372 Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Diabetes
Primary: Mean Change in A1C From Baseline to 1 Year — 0.034 percentage
N/A N=150 TPAP for Comfort in OSA
Obstructive Sleep Apnea
Primary: CPAP v TPAP Patient Preference at 9 cmH2O Baseline Pressure, TPAP Drop 2+2 cmH2O — 69.3 percentage of total participants
Phase 3 N=1,196 Technology-Assisted Cholesterol Trial in Consumers (TACTiC)
High Cholesterol
Primary: Overall Correct Initial TASS Outcome, Worst Case Imputation, First Co-Primary Endpoint (Self-Selection Population) — 1085 Participants
N/A N=115 Post-Authorization Study Evaluating Safety Of Tigecycline
Intra-Abdominal Infections · Skin Disease, Infectious · Soft Tissues Infections
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 11; 45; 4; 28 participants
N/A N=120 Adolescent Trauma Recovery and Stress Disorders Collaborative Care (ATRSCC) Model Program Trial
Post-traumatic Stress Disorder · Alcohol Abuse · Alcohol Dependence
Primary: Number of Patients With High Levels of Adolescent PTSD Symptoms — 9; 12; 11; 12 Participants — p=0.71
N/A N=6,718 Transthyretin Amyloidosis Outcome Survey (THAOS)
Transthyretin Gene Mutations · Transthyretin Amyloidosis
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 621; 175; 66; 4 Participants
N/A N=53 Biomechanical Validation of the Transfer Assessment Instrument (TAI)
Spinal Cord Injury
Primary: Transfer Performance (TAI Scores Part 1) — 6.31; 9.92 units on a scale